Press Releases Year None20212020201920182017 May 14, 2021 SpringWorks Therapeutics to Present at the Cowen 2nd Annual Oncology Innovation Summit PDF Version May 10, 2021 SpringWorks Therapeutics Appoints Dr. Mike Burgess as Head of Research and Development PDF Version May 6, 2021 SpringWorks Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Highlights PDF Version May 6, 2021 SpringWorks Therapeutics Expands Targeted Oncology Pipeline with Exclusive Worldwide License to TEAD Inhibitor Portfolio PDF Version April 12, 2021 Allogene Therapeutics and SpringWorks Therapeutics Announce Dosing of First Patient in Phase 1 Study Evaluating ALLO-715 in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma PDF Version April 1, 2021 SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b Combination Study Evaluating Nirogacestat and Janssen’s BCMA Bispecific Antibody Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma PDF Version March 22, 2021 SpringWorks Therapeutics Appoints Bhavesh Ashar as Chief Commercial Officer PDF Version February 25, 2021 SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights PDF Version February 25, 2021 SpringWorks Therapeutics Reports Interim Data from Phase 2b ReNeu Trial of Mirdametinib for Patients with NF1-PN and Provides Trial Update PDF Version February 22, 2021 SpringWorks Therapeutics to Present at Upcoming Investor Conferences PDF Version Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Next page next › Last page last »
May 14, 2021 SpringWorks Therapeutics to Present at the Cowen 2nd Annual Oncology Innovation Summit PDF Version
May 10, 2021 SpringWorks Therapeutics Appoints Dr. Mike Burgess as Head of Research and Development PDF Version
May 6, 2021 SpringWorks Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Highlights PDF Version
May 6, 2021 SpringWorks Therapeutics Expands Targeted Oncology Pipeline with Exclusive Worldwide License to TEAD Inhibitor Portfolio PDF Version
April 12, 2021 Allogene Therapeutics and SpringWorks Therapeutics Announce Dosing of First Patient in Phase 1 Study Evaluating ALLO-715 in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma PDF Version
April 1, 2021 SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b Combination Study Evaluating Nirogacestat and Janssen’s BCMA Bispecific Antibody Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma PDF Version
March 22, 2021 SpringWorks Therapeutics Appoints Bhavesh Ashar as Chief Commercial Officer PDF Version
February 25, 2021 SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights PDF Version
February 25, 2021 SpringWorks Therapeutics Reports Interim Data from Phase 2b ReNeu Trial of Mirdametinib for Patients with NF1-PN and Provides Trial Update PDF Version
